Presented at the Annual Meeting of the American Society for Radiation Oncology; October 28-31, 2012; Boston, MA.
Trends in the use of postprostatectomy therapies for patients with prostate cancer: A Surveillance, Epidemiology, and End Results Medicare analysis
Version of Record online: 10 JUL 2013
© 2013 American Cancer Society
Volume 119, Issue 18, pages 3295–3301, 15 September 2013
How to Cite
Sheets, N. C., Hendrix, L. H., Allen, I. M. and Chen, R. C. (2013), Trends in the use of postprostatectomy therapies for patients with prostate cancer: A Surveillance, Epidemiology, and End Results Medicare analysis. Cancer, 119: 3295–3301. doi: 10.1002/cncr.28222
- Issue online: 4 SEP 2013
- Version of Record online: 10 JUL 2013
- Manuscript Accepted: 21 MAY 2013
- Manuscript Revised: 18 MAY 2013
- Manuscript Received: 25 MAR 2013
- 4Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–2930., , , et al.
- 9National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology 2012: prostate cancer. nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed June 22, 2012.
- 10Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;(4):CD006019., , , , , .
- 17Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(suppl 8):IV-43–IV-48., , , , , .
- 18Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002;40(suppl 8):IV-49–IV-54., , , , , .
- 21The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2–4 N0 radical prostatectomy patients [published online ahead of print August 10, 2012]. Eur Urol., , , et al.
- 23Initial report of RTOG 9601: a phase III trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2–3, N0 disease, and elevated PSA levels. Int J Radiat Oncol Biol Phys. 2010;78:S27., , , et al.